CannaGrowth.com | Will Investment Bank’s Support Help Win a New York Marijuana License?
15876
post-template-default,single,single-post,postid-15876,single-format-standard,ajax_fade,page_not_loaded,,vertical_menu_enabled,side_area_uncovered_from_content,qode-theme-ver-7.2,wpb-js-composer js-comp-ver-4.5.1,vc_responsive

Will Investment Bank’s Support Help Win a New York Marijuana License?

07 Jul Will Investment Bank’s Support Help Win a New York Marijuana License?

The state of New York is expected to name the five winners of its coveted medical-marijuana licenses any day now, but one bidder thinks he has a leg up over the competition thanks to an influx of cash from an unusual source: a major investment bank.

Ari Hoffnung, a 2005 Bronx City Council candidate whose Fiorello Pharmaceuticals was named after legendary New York City Mayor Fiorello La Guardia, asserted that his company’s partnership with CastleOak Securities, a subsidiary of major Wall Street firm Cantor Fitzgerald, places his bid head-and-shoulders above the rest. He said he is the only applicant to publicly announce a partnership with a leading investment bank.

“There are, unfortunately, not too many banks who are willing to work with the medical-marijuana industry,” Mr. Hoffnung said. “I’m grateful that CastleOak stepped up to the plate and worked in partnership with us.”

CastleOak helped Mr. Hoffnung’s Fiorello Pharmaceuticals raise $7.5 million in Series A financing, an amount he hopes to double if awarded a state license. Marijuana investors estimate startup costs for companies in New York to be a minimum of $25 million. A spokeswoman for the bank did not immediately return a request for comment. [Read more at Crain’s New York Business]

The post Will Investment Bank’s Support Help Win a New York Marijuana License? appeared first on Cannabis Business Executive.

No Comments

Sorry, the comment form is closed at this time.